Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors

Table 1

Demographic characteristics and medical history.

Participant	Age	Gender	Pathology, WHO grade	Location	Surgery prior to the study	Treatment prior to the study	Status at the time of study	Aerobic glycolysis
1	57	M	GBM, IV	R temporooccipital	None	None	Newly diagnosed	Elevated
2	71	M	GBM, IV	R temporal	Resection	IMRT, TEM	Recurrent	Elevated
3	69	M	GBM, IV	L temporoparietal	Resection	IMRT, TEM	Recurrent	Elevated
4	49	M	GBM, IV	L temporal	Resection	IMRT, TEM, and Avastin	Recurrent	Elevated
5	58	M	GBM, IV	R occipital	Resection	IMRT, TEM	Recurrent	Elevated
6	42	M	PNET, IV	L temporal	Resection	IMRT, Vincristine, and Cisplatin	Recurrent	Elevated
7	43	M	AA, III	R frontal	Resection	IMRT, TEM	Recurrent	Elevated
8	57	F	AOA, III	L temporooccipital	Biopsy	IMRT, TEM	Progression	Elevated
9	56	M	AOA, III	L parietal	Biopsy	IMRT, TEM	Stable disease	Elevated
10	57	M	PNET, IV	R temporal	Resection	WBRT, TEM	Residual/recurrent	Not elevated
11	29	M	AO, III	L frontal	Resection	IMRT, TEM	Stable disease	Not elevated
12	30	F	AA, III	L frontoparietal	Biopsy	None	Newly diagnosed	Not elevated
13	43	M	FAD; GBM, IV	R frontal	None	None	FAD	Asymmetry
14	40	M	AO, III	L frontal	Resection	IMRT, TEM	Recurrent	Elevated

M, male; F, female; WHO, World Health Organization; GBM, glioblastoma; PNET, primitive neuroectodermal tumor; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic oligodendroglioma; FAD, familial Alzheimer’s disease; R, right; L, left; IMRT, intensity-modulated radiation therapy; WBRT, whole brain radiation therapy; TEM, Temozolomide.